Doctor payoffs
Mike Licht / Flickr Creative Commons

Physicians earn their livings from patient care, but for many, fees are not their only source of income.

New data released under the Affordable Care Act shows how much individual doctors receive from pharmaceutical and medical device companies. Several physicians in the Triangle receive thousands of dollars.

Host Frank Stasio talks with Triangle Business Journal reporter Jason deBruyn about the fees and access to the data.

A picture of Tamiflu tablets.
Alcibiades / Wikipedia

Flu season has pharmacies scrambling to keep an antiviral drug called Tamiflu in stock.

Duke University Pharmacy Professor Richard Drew says unlike vaccines, Tamiflu works to treat and stop the spread of the disease.

“It's both a preventative and a treatment strategy,” Drew explains. “And, certainly, for those people who have a serious illness and require hospitalization, it's a very important drug.”

Sarah Lee manages the pharmacy supply chain for UNC Hospitals. She says this time each year, the demand for Tamiflu goes up exponentially.



Pharmaceutical giant GlaxoSmithKline eliminated 900 jobs yesterday.

Image of GlaxoSmithKline headquarters in west London.
Flickr/Ian Wilson


Pharmaceutical player GlaxoSmithKline is laying off hundreds of workers in its American facilities, and the bulk of these job cuts are in Research Triangle Park.

A picture of a stethoscope.
jasleen_kaur / Flickr/Creative Commons

Health care organizations in North Carolina are expanding an initiative to see how doctors and pharmacists cooperate to streamline patient care.

Community Care of North Carolina has already set up a program in which 3,000 GlaxoSmithKline employees see doctors who coordinate all their treatment.

But CCNC President Doctor Allen Dobson says that primary care physicians don't always know all the medications a patient is taking, especially if they're seeing other specialists for multiple conditions.


Reynolds American and Lorillard, two of the country’s biggest tobacco producers, announced a merger yesterday that is expected to reshape the tobacco industry. 

Assorted pharmaceuticals
creative commons


A recent deal between the biopharmaceutical companies GlaxoSmithKline and Novartis may mean more jobs and more attention for the Research Triangle. Plus, the $1.1 billion sale of Furiex pharmaceuticals increases possibilities for investment in the area. Meanwhile, Mooresville's Vestiq Holdings, a much smaller pharmaceutical company, is filing for bankruptcy. 


Big changes and asset swaps in the pharmaceutical world are happening this week, but the Triangle should be spared of any fall-out.

One of the big moves in this chess game includes Switzerland-based Novartis agreeing to spend up to $16 billion for GlaxoSmithKline’s cancer drug business in Pennsylvania.

Federal regulators this month opened a new era in the treatment of a deadly liver virus that infects three to five times more people than HIV. Now the question is: Who will get access to the new drug for hepatitis C, and when?

The drug Sovaldi will cost $1,000 per pill. A typical course of treatment will last 12 weeks and run $84,000, plus the cost of necessary companion drugs. Some patients may need treatment for twice as long.

NC State University

North Carolina State University recently beefed up its toxicology database, which could help revolutionize pharmaceutical research.

NC State's Comparitive Toxicogenomics Database already cataloged the harmful health impacts of environmental chemicals, like arsenic. Then pharmaceutical giant Pfizer collaborated with the CTD to add unintended side effects of therapeutic drugs.